Haleos Labs Limited Postal Ballot Notice for Material Related Party Transaction
Haleos Labs Limited has issued an official postal ballot notice seeking shareholder approval for a material related party transaction involving a ₹20 crores corporate guarantee for its subsidiary Mahi Drugs Private Limited's External Commercial Borrowing facility from RBL Bank. The e-voting process will be conducted from March 31 to April 29, 2026, with results to be declared on May 1, 2026.
*this image is generated using AI for illustrative purposes only.
Haleos Labs Limited has issued an official postal ballot notice seeking shareholder approval for a material related party transaction involving the issuance of a corporate guarantee. The company will conduct the voting process exclusively through electronic means, with the cut-off date scheduled for March 27, 2026.
Transaction Details and Resolution
The postal ballot addresses a single ordinary resolution for approving a material related party transaction. The resolution seeks approval for issuing a corporate guarantee in favour of RBL Bank Limited to secure an External Commercial Borrowing facility availed by Mahi Drugs Private Limited, the company's material subsidiary.
| Transaction Parameter: | Details |
|---|---|
| Resolution Type: | Ordinary Resolution |
| Guarantee Amount: | USD 2,200,000 (₹20.00 crores) |
| Beneficiary Bank: | RBL Bank Limited |
| Related Party: | Mahi Drugs Private Limited (60% subsidiary) |
| Purpose: | Secure External Commercial Borrowing Facility |
| Tenure: | 72 months (including 12 months moratorium) |
E-Voting Timeline and Process
The company has established a comprehensive timeline for the postal ballot process. Shareholders whose names appear in the Register of Members or List of Beneficial Owners as on the cut-off date will be entitled to vote through remote e-voting only.
| Event: | Date/Time |
|---|---|
| Board Approval Date: | February 11, 2026 |
| Cut-off Date: | March 27, 2026 |
| Notice Dispatch Date: | March 30, 2026 |
| E-voting Commencement: | March 31, 2026 (9:00 am) |
| E-voting Conclusion: | April 29, 2026 (5:00 pm) |
| Results Declaration: | May 1, 2026 |
Appointed Officials and Agencies
The Board of Directors has appointed key officials to facilitate the postal ballot process. Mr. C. Sudhir Babu (FCS No.7666), a practicing company secretary, has been designated as the scrutinizer to conduct the postal ballot and e-voting process. Central Depository Services (India) Limited has been appointed as the authorized agency to provide the remote e-voting platform to all members.
Related Party Transaction Analysis
The transaction qualifies as a material related party transaction under SEBI regulations. The guarantee amount represents 5.80% of the company's annual consolidated turnover of ₹344.72 crores and 47.31% of Mahi Drugs' annual standalone turnover of ₹42.27 crores.
| Financial Metrics: | Amount (₹ crores) |
|---|---|
| Haleos Labs Consolidated Turnover: | 344.72 |
| Mahi Drugs Standalone Turnover: | 42.27 |
| Mahi Drugs Net Worth: | 38.72 |
| Mahi Drugs PAT: | (3.44) |
| Previous Year RPT Value: | 36.61 |
| Current Year RPT Value (Q3): | 25.01 |
Regulatory Compliance and Justification
The postal ballot process is being conducted in accordance with Regulation 30 of SEBI (Listing Obligations & Disclosure Requirements) Regulations, 2015. The company has justified the transaction as commercially prudent, enabling the subsidiary to secure funding at competitive terms and strengthening its financial position. Mahi Drugs has obtained a credit rating of IVR BB+ with stable outlook from Infomerics Valuation and Rating Limited.
Historical Stock Returns for Haleos
| 1 Day | 5 Days | 1 Month | 6 Months | 1 Year | 5 Years |
|---|---|---|---|---|---|
| +1.01% | +4.91% | +7.64% | +19.45% | -19.19% | +109.07% |
How will Mahi Drugs utilize the USD 2.2 million External Commercial Borrowing facility to improve its financial performance and reverse the negative PAT of ₹3.44 crores?
What impact could this significant guarantee exposure (47.31% of Mahi Drugs' turnover) have on Haleos Labs' credit rating and future borrowing capacity?
Will Haleos Labs consider increasing its stake in Mahi Drugs beyond the current 60% to have greater control over the subsidiary's operations and financial decisions?
Access Market Heat-map & Insights 
Create, Save & Share your Screener 
Use 200+ Screening Filters 
